-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：印度最大的製藥公司、全球第四大專業仿製藥公司Sun Pharma今日出人意料地宣布，已達成協議，將以每股14美元的價格收購Organon，該交易為全現金交易，企業價值達117.5億美元。該交易預計將於2027年初完成，合併後將打造一家全球排名前25的製藥公司，合併後的收入約為124億美元，使Sun Pharma成為女性健康領域排名前三的公司，以及全球第七大生物相似藥公司。我們認為此次收購具有戰略意義，因為Organon在過去一年中面臨著業績和公司治理方面的問題。此前，一項內部調查發現Organon在美國存在與其主要避孕產品Nexplanon相關的不當批發行為，並且前首席執行官K. Ali突然離職。消息公佈後，OGN股價今日上漲17%。基於2027年每股盈餘預期3.8倍的本益比，我們將目標股價從7美元上調至14美元。我們維持2026年每股收益預期3.62美元及2027年每股收益預期3.71美元不變。
Related Articles
Insider Trading
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
$LFST
Australia
Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.
$CLS
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.
$AMP